Schultz RM - Search Results

1

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.

Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG. Tonkinson JL, et al. Among authors: schultz rm. Cancer Chemother Pharmacol. 1997;39(6):521-31. doi: 10.1007/s002800050608. Cancer Chemother Pharmacol. 1997. PMID: 9118464

2

Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.

Zhu G, Conner SE, Zhou X, Chan HK, Shih C, Engler TA, Al-Awar RS, Brooks HB, Watkins SA, Spencer CD, Schultz RM, Dempsey JA, Considine EL, Patel BR, Ogg CA, Vasudevan V, Lytle ML. Zhu G, et al. Among authors: schultz rm. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3057-61. doi: 10.1016/j.bmcl.2004.04.033. Bioorg Med Chem Lett. 2004. PMID: 15149644

3

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

Hamdouchi C, Keyser H, Collins E, Jaramillo C, De Diego JE, Spencer CD, Dempsey JA, Anderson BD, Leggett T, Stamm NB, Schultz RM, Watkins SA, Cocke K, Lemke S, Burke TF, Beckmann RP, Dixon JT, Gurganus TM, Rankl NB, Houck KA, Zhang F, Vieth M, Espinosa J, Timm DE, Campbell RM, Patel BK, Brooks HB. Hamdouchi C, et al. Among authors: schultz rm. Mol Cancer Ther. 2004 Jan;3(1):1-9. Mol Cancer Ther. 2004. PMID: 14749470

4

Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NB, Anderson BD, Campbell RM, Vasudevan V, Lytle ML. Engler TA, et al. Among authors: schultz rm. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2261-7. doi: 10.1016/s0960-894x(03)00461-x. Bioorg Med Chem Lett. 2003. PMID: 12824014

5

Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate.

Schultz RM. Schultz RM. Prog Drug Res. 2005;63:275-300. doi: 10.1007/3-7643-7414-4_11. Prog Drug Res. 2005. PMID: 16265884 Review. No abstract available.

6

Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.

Worzalla JF, Shih C, Schultz RM. Worzalla JF, et al. Among authors: schultz rm. Anticancer Res. 1998 Sep-Oct;18(5A):3235-9. Anticancer Res. 1998. PMID: 9858888

7

Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.

Schultz RM, Shih C, Wood PG, Harrison SD, Ehlhardt WJ. Schultz RM, et al. Oncol Rep. 1998 Sep-Oct;5(5):1089-94. doi: 10.3892/or.5.5.1089. Oncol Rep. 1998. PMID: 9683814

8

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Mendelsohn LG, Shih C, Schultz RM, Worzalla JF. Mendelsohn LG, et al. Among authors: schultz rm. Invest New Drugs. 1996;14(3):287-94. doi: 10.1007/BF00194532. Invest New Drugs. 1996. PMID: 8958184

9

A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.

Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG. Habeck LL, et al. Among authors: schultz rm. Cancer Res. 1994 Feb 15;54(4):1021-6. Cancer Res. 1994. PMID: 8313357

10

Newer antifolates in cancer therapy.

Schultz RM. Schultz RM. Prog Drug Res. 1995;44:129-57. doi: 10.1007/978-3-0348-7161-7_4. Prog Drug Res. 1995. PMID: 7644664 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results